Novartis

Novartis
Share
Novartis Oncology discovers and develops innovative therapies that help change the way patients live with cancer and blood disorders, including Gleevec® (imatinib mesylate), Tasigna® (nilotinib), Afinitor® (everolimus), Zometa® (zoledronic acid), Femara® (letrozole tablets), Sandostatin® LAR Depot (octreotide acetate for injectable suspension), and Exjade® (deferasirox). Novartis Oncology has one of the broadest and most comprehensive pipelines in the industry.

Novartis

 •  August 30

First-in-class therapy showed an 83% (52/63) overall remission rate in this patient population with limited treatment options and historically poor outcomes [1],[2]. Novel approach to cancer treatment is the result of pioneering CAR-T cell therapy collaboration with University of Pennsylvania Reproducible, flexible and validated manufacturing...

Novartis

 •  August 27

Review of blinded, pre-planned oncology safety analyses revealed a 77% reduction in lung cancer mortality and 67% reduction in lung cancer cases in patients treated with 300mg of ACZ885 CANTOS is the first Phase III clinical trial to support a long-established hypothesis from pre-clinical models that inhibition of IL-1ß impacts cancer incidence...

Novartis

 •  July 21

Recommendation based on largest trial in FLT3-mutated AML to date, showing 23% reduction in the risk of death with Rydapt treatment regimen[1]
If approved, Rydapt would represent the first targeted treatment for newly diagnosed FLT3-mutated AML in the EU
Rydapt would be the first and only EMA-approved therapy for advanced SM, a group of rare,...

Novartis

 •  June 29

In ALK-positive advanced NSCLC patients, Zykadia demonstrated superior median progression-free survival (PFS) compared to SOC chemotherapy with maintenance[1]
Zykadia benefit was also seen in patients with brain metastases[1]
Approximately 3-7% of all patients with NSCLC have an ALK gene rearrangement[2] Basel, June 29, 2017 - Novartis today...

Novartis

 •  June 23

83% of patients achieved complete remission (CR) or CR with incomplete blood count recovery within 3 months of treatment with CTL019; consistent with interim ELIANA data
Data evaluating 63 patients demonstrate relapse-free survival and probability of survival in a majority of patients at six months
Advances in CTL019 and ELIANA result from...

Novartis

 •  June 7

At interim analysis, three-month overall response rate (ORR) was 45%, with 37% complete response (CR); all patients in CR at three months remained in CR at data cutoff Best ORR was 59%, with 43% achieving CR; full results expected to be available later in 2017 and will serve as basis for US and EU regulatory submissions Global, multi-center Phase...

Novartis

 •  June 6

Phase I/II study to evaluate Mekinist® (trametinib) in combination with Opdivo® (nivolumab) and Opdivo + Yervoy® (ipilimumab)
Collaboration expands upon existing clinical investigation of Opdivo combination with Novartis investigational and marketed therapies Basel, June 5, 2017 - Novartis today announced it has entered into a clinical research...

Novartis

 •  May 22

Arzerra significantly improved PFS when added to fludarabine + cyclophosphamide (median 28.9 mos vs 18.8 mos) after initial treatment stopped working Patients receiving Arzerra plus existing CLL treatments also had a higher overall response rate (84% vs 68%) compared to fludarabine and cyclophosphamide alone Chronic lymphocytic leukemia (CLL) is...

Novartis

 •  April 20

NIH study found 58% of patients with treatment-naïve severe aplastic anemia (SAA) achieved a complete response when eltrombopag was given at the initiation of and concurrently with standard immunosuppressive therapy[1]
The historical complete response rate was 10% for untreated patients with SAA on immunosuppressive therapy alone[1]
Findings...

Novartis

 •  April 18

Designation prioritizes investigational CTL019 (tisagenlecleucel) as a potential treatment for adult patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL) R/r DLBCL, an aggressive cancer with limited options, is the second indication for CTL019 to receive Breakthrough Therapy designation Advances in CTL019 result from...